SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 72 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,074,000 | -63.4% | 902,907 | +0.2% | 0.36% | -59.9% |
| Q4 2021 | $2,936,000 | -27.1% | 900,677 | 0.0% | 0.88% | -31.0% |
| Q3 2021 | $4,026,000 | -7.7% | 900,677 | +12.6% | 1.28% | +18.4% |
| Q2 2021 | $4,360,000 | +195.8% | 800,000 | +379.7% | 1.08% | +271.2% |
| Q3 2020 | $1,474,000 | -49.3% | 166,780 | -38.9% | 0.29% | -65.6% |
| Q2 2020 | $2,909,000 | +4.7% | 272,902 | -41.8% | 0.85% | -8.8% |
| Q1 2020 | $2,778,000 | -10.4% | 468,532 | +4.5% | 0.93% | +26.2% |
| Q4 2019 | $3,099,000 | – | 448,532 | – | 0.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |